{
 "PrintNo":"A500","Session":2025,"Chamber":"ASSEMBLY","BillType":"Assembly","Published":"2025-01-06T12:08:47.774405Z",
 "Status":"IN_ASSEMBLY_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_ASSEMBLY_COMM","Date":"2025-01-08","Committee":"Health"}],
 "Actions":[{"Text":"REFERRED TO HEALTH","Date":"2025-01-08","Chamber":"ASSEMBLY"}],
 "Sponsors":[{"ID":675,"Name":"Phil Steck","Short":"STECK"}],
 "Title":"Establishes a generic drug research and development laboratory and production facility and the empire state biosimilar insulin initiative",
 "Summary":"Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.",
 "LawSection":"Public Health Law","LawCode":"Add Art 2-A Title IV §§285 - 288, Pub Health L",
 "ActClause":"AN ACT to amend the public health law, in relation to establishing a generic drug research and development laboratory and production facility and the empire state biosimilar insulin initiative",
 "PreviousVersions":["A9535-2023"]
}